Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1995-6-5
|
| pubmed:abstractText |
The physical and biological attributes of 117mSn(4+)-DTPA indicate that it should be an effective agent for palliative therapy of painful bony metastatic disease. The aim of this study was to evaluate whether or not this agent could effectively reduce pain while sparing the hemopoietic marrow from adverse effects.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0161-5505
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
36
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
725-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7537804-Bone Marrow,
pubmed-meshheading:7537804-Bone Neoplasms,
pubmed-meshheading:7537804-Female,
pubmed-meshheading:7537804-Humans,
pubmed-meshheading:7537804-Male,
pubmed-meshheading:7537804-Pain,
pubmed-meshheading:7537804-Palliative Care,
pubmed-meshheading:7537804-Pentetic Acid
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study.
|
| pubmed:affiliation |
Medical Department, Brookhaven National Laboratory, Upton, New York, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Clinical Trial, Phase II
|